Kuros Biosciences reports results for the full year 2022

Schlieren (Zurich), Switzerland, March 15, 2023 – Kuros Biosciences today announces continued robust progress with its results for full year 2022, increasing MagnetOs direct sales by 75% and completing enrollment of the randomized stage of the Phase 2 spine study for Fibrin-PTH, confirming its successful transition into a fully-fledged orthobiologics...

read more

Results published demonstrating accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging

Zurich-Schlieren, Switzerland, March 9, 2023. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that new results evaluating Proclarix® in combination with imaging were published in BJU International[1]. The early detection of clinically significant prostate cancer decreases prostate cancer mortality. The use of multiparametric magnetic resonance imaging...

read more